Virtual Library
Start Your Search
Zhangzhou Huang
Author of
-
+
P1.03 - Biology (Not CME Accredited Session) (ID 935)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 5
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.03-02 - Analysis of SMAD4 Aberrations in Chinese Patients with Non-Small-Cell Lung Cancer (ID 11107)
16:45 - 18:00 | Author(s): Zhangzhou Huang
- Abstract
Background
Mothers against decapentaplegic homolog 4 (SMAD4) is an important protein in cancers. It plays pivotal roles in cellular pathways, including apoptosis. While the genetic locus of SMAD4 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring SMAD4 mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 451 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of SMAD4 mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
SMAD4 gene mutation rate was 1.77% (8/451) in non-small cell lung cancer, including R361H (3 patients), C324Y (1 patient), E526Q (1 patient), Q289* (1 patient), D493G (1 patient) and P522R (1 patient), and median overall survival (OS) for these patients was 13.0 months. Among them, all patients were SMAD4 gene with co-occurring mutation. Briefly, patients with (n=2) or without (n=6) co-occurring EGFR mutations had a median OS of 10.0 months and 15.0 months respectively (P=0.18); patients with (n=5) or without (n=3) co-occurring TP53 mutations had a median OS of 10.0 months and 19.5 months respectively (P=0.18); patients with (n=3) or without (n=5) co-occurring KRAS mutations had a median OS of 10.0 months and 15.0 months respectively (P=0.30); patients with (n=3) or without (n=5) co-occurring CDKN2A mutations had a median OS of 10.0 months and 15.0 months respectively (P=0.22).
8eea62084ca7e541d918e823422bd82e Conclusion
There are some significant difference of clinical features in SMAD4 gene mutations with smoking advance NSCLC. SMAD4 gene inactivation is associated with poorer prognosis in patients with NSCLC.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-03 - Molecular Characteristics of Chinese Patients with TSC2-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study (ID 11118)
16:45 - 18:00 | Presenting Author(s): Zhangzhou Huang
- Abstract
Background
Tuberous sclerosis complex 2 (TSC2) is a rare autosomal dominant disorder causing benign tumors in the brain and other vital organs. There is some clinical evidence for the use of TSC2 mutations as prognostic and predictive biomarker. The aim of this study is to investigate mutations and prognosis of NSCLC harboring TSC2 mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 554 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of TSC2 mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
TSC2 gene mutation rate was 4.51% (25/554) in non-small cell lung cancer, including M286V (2 patients), R1743W (1 patient), V550G (1 patient), D1004Y (1 patient), E546K (1 patient), K1065E (1 patient), R1329P (1 patient), K1585R (1 patient), S1221L (1 patient), A678T (1 patient), F15V (1 patient), D1406N (1 patient), P237L (1 patient), V1144M (1 patient), V1034I (1 patient), D1406N (1 patient), N1224I (1 patient), Q371H (1 patient), P1770S (1 patient), R1268G), A1141T (1 patient), R537C (1 patient), M649I (1 patient) and A1294V (1 patient), and median overall survival (OS) for these patients was 20.0 months. Among them, 23 patients with co-occurring mutations had a median OS of 20.0 months, and median OS of the 2 patients without complex mutations was 7.0 months. No statistically significant difference was found between the two groups (P=0.15). Briefly, patients with (n=8) or without (n=17) co-occurring EGFR mutations had a median OS of 19.0 months and 20.0 months respectively (P=0.93); patients with (n=18) or without (n=7) co-occurring TP53 mutations had a median OS of 20.0 months and 27.5 months respectively (P=0.67).
8eea62084ca7e541d918e823422bd82e Conclusion
There is no significant difference of molecular features in TSC2 gene mutations in NSCLC. Patients with complex mutations benefited more from therapy than those with single mutations. Next generation sequencing provides a simplified strategy and reasonably high detection rate for TSC2 mutation, which suggested application of the strategies into clinical molecular diagnostics.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-08 - Detection of PTCH1 Gene Variants in Non-Small Cell Lung Cancer Patients from China (ID 11116)
16:45 - 18:00 | Author(s): Zhangzhou Huang
- Abstract
Background
Recently, the Patched homolog 1 gene (PTCH1) gene mutations are identified in non-small-cell lung cancer (NSCLC). While the genetic spectrum of PTCH1 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring PTCH1 mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 269 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of PTCH1 mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
PTCH1 gene mutation rate was 6.32% (17/269) in non-small cell lung cancer, including S827G (2 patients), G445S (1 patient), A1130T (1 patient), L1036F (1 patient), E173D (1 patient), P1210L (1 patient), Y820* (1 patient), D710E (1 patient), C37W (1 patient), N258I (1 patient), F614Y (1 patient), P681S (1 patient), V1381G (1 patient), G37R (1 patient), A741V (1 patient) and P1282L plus R893H (1 patient), and median overall survival (OS) for these patients was 18.0 months. Among them, all patients were PTCH1 gene with co-occurring mutation. Briefly, patients with (n=5) or without (n=12) co-occurring EGFR mutations had a median OS of 22.0 months and 18.0 months respectively (P=0.25); patients with (n=11) or without (n=6) co-occurring TP53 mutations had a median OS of 18.0 months and 14.0 months respectively (P=0.28); patients with (n=2) or without (n=15) co-occurring BRAF mutations had a median OS of 4.0 months and 18.0 months respectively (P=0.14); patients with (n=2) or without (n=8) co-occurring PIK3CA mutations had a median OS of 17.0 months and 18.0 months respectively (P=0.96).
8eea62084ca7e541d918e823422bd82e Conclusion
PTCH1 gene mutation coexists with other gene mutation in NSCLC. EGFR, TP53, BRAF and PIK3CA gene accompanied may have less correlation with PTCH1 mutation in NSCLC patients. Analysis of PTCH1 mutations shows promise as a way to refine individual patients with NSCLC, and provides more insight into effective treatment strategies for patients with PTCH1 mutations.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-10 - The Molecular Spectrum of NF1 Variants in Chinese Non-Small-Cell Lung Cancer Patients (ID 11111)
16:45 - 18:00 | Author(s): Zhangzhou Huang
- Abstract
Background
Activation of the RAS/MAPK pathway is critical in non-small-cell lung cancer. Non-small-cell lung cancer can be grouped into four molecular subtypes based on their main genetic driver: EGFR-mutant, ALK-fusion, ROS1-fusion, and triple wild-type tumors. The NF1 protein, neurofibromin 1, negatively regulates RAS proteins through GTPase activity. Somatic mutations in NF1 cause neurofibromatosis type I, a common genetic tumor syndrome caused by dysregulation of the RAS/MAPK pathway, ie, RAS pathy. While the genetic sites of NF1 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring NF1 mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 337 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of NF1 mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
NF1 gene mutation rate was 6.23% (21/337) in non-small cell lung cancer, including M645V (3 patients), A1998V (1 patient), Q83E (1 patient), P654T (1 patient), Q912* (1 patient), C324* (1 patient), C1032S (1 patient), I1628M (1 patient), L43V (1 patient), A861Qfs*17 (1 patient), Q239E (1 patient), D1623N (1 patient), T586Vfs*18 (1 patient), R2328C (1 patient), E41* (1 patient), V437Nfs*35 (1 patient), P2046L plus G1219* (1 patient), D2055Mfs*6 plus T2133Sfs*45 (1 patient) and C1288F plus K2252* (1 patient), and median overall survival (OS) for these patients was 10.0 months. Among them, all patients were NF1 gene with co-occurring mutation. Briefly, patients with (n=3) or without (n=18) co-occurring EGFR mutations had a median OS of 15.5 months and 10.0 months respectively (P=0.69); patients with (n=18) or without (n=3) co-occurring TP53 mutations had a median OS of 10.0 months and 6.0 months respectively (P=0.21); patients with (n=3) or without (n=18) co-occurring RB1 mutations had a median OS of 19.5 months and 9.0 months respectively (P=0.27); patients with (n=3) or without (n=18) co-occurring SMARCA4 mutations had a median OS of 20.5 months and 9.0 months respectively (P=0.19).
8eea62084ca7e541d918e823422bd82e Conclusion
Patients with complex mutations benefited more from therapy than those with single mutations. NF1 genetic alter occurs in a subset of NSCLC, and improved understanding of the implications of NF1 aberrations is critical for the identification of therapeutic target candidates.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-26 - Analysis of DDR2 Gene Aberrations in Chinese Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis (ID 11105)
16:45 - 18:00 | Author(s): Zhangzhou Huang
- Abstract
Background
Recently, Mutations in discoidin domain receptor 2 (DDR2) gene were recently identified as promising molecular targets in non-small-cell lung cancer. While the genetic spectrum of DDR2 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring DDR2 mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 283 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of DDR2 mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
DDR2 gene mutation rate was 3.18% (9/283) in non-small cell lung cancer, including S311N (3 patients), E44K (1 patient), R709Q (1 patient), T564I (1 patient), R742Q (1 patient), G206* (1 patient) and M117I (1 patient), and median overall survival (OS) for these patients was 20.0 months. Among them, all patients were DDR2 gene with co-occurring mutation. Briefly, patients with (n=6) or without (n=3) co-occurring EGFR mutations had a median OS of 20.0 months and 9.0 months respectively (P=0.29); patients with (n=4) or without (n=5) co-occurring TP53 mutations had a median OS of 17.0 months and 21.5 months respectively (P=0.63); patients with (n=2) or without (n=7) co-occurring KRAS mutations had a median OS of 13.5 months and 20.0 months respectively (P=0.82); patients with (n=2) or without (n=7) co-occurring PTPRD mutations had a median OS of 15.0 months and 20.0 months respectively (P=0.96).
8eea62084ca7e541d918e823422bd82e Conclusion
DDR2 mutations were observed in 3.18 % of cases of NSCLC. DDR2-mutated NSCLC can exhibit other driver gene alterations. No clinical characteristics were significantly associated with DDR2 mutation.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.01-39 - Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress (ID 11110)
12:00 - 13:30 | Author(s): Zhangzhou Huang
- Abstract
Background
As the first epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo. The phase III clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients with advanced non-small cell lung cancer (NSCLC) compared with gefitinib. The aim of this study is to investigate the acquired EGFR T790M situation of the non-small cell lung cancer patients who received icotinib treatment progress.
a9ded1e5ce5d75814730bb4caaf49419 Method
The ARMS method was used to detect the samples in 209 cases of EGFR 19del or L858R mutation non-small cell lung cancer.
4c3880bb027f159e801041b1021e88e8 Result
There were 123 cases accompanied 19del and 86 cases accompanied L858R in 209 cases non-small cell lung cancer samples who received icotinib treatment progress, the acquired T790M mutation type patients was 45.93% (96/209), icotinib treatment. resistance after the acquired T790M mutation with 19 del/L858R group had statistical difference (P<0.034).
8eea62084ca7e541d918e823422bd82e Conclusion
19 del patients who received treatment for icotinib are more likely to appear acquired T790M mutation than L858R patients from NSCLC, and we should attach importance to it.
6f8b794f3246b0c1e1780bb4d4d5dc53
